These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32117285)

  • 1. Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor.
    Georgescu MT; Moorehead PC; Liu T; Dumont J; Scott DW; Hough C; Lillicrap D
    Front Immunol; 2020; 11():138. PubMed ID: 32117285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII-Fc Activates Natural Killer Cells
    Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
    Front Immunol; 2021; 12():692157. PubMed ID: 34262568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
    Lagassé HAD; Ou J; Sauna ZE; Golding B
    Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
    Krishnamoorthy S; Liu T; Drager D; Patarroyo-White S; Chhabra ES; Peters R; Josephson N; Lillicrap D; Blumberg RS; Pierce GF; Jiang H
    Cell Immunol; 2016 Mar; 301():30-9. PubMed ID: 26775174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.
    Kis-Toth K; Rajani GM; Simpson A; Henry KL; Dumont J; Peters RT; Salas J; Loh C
    Blood Adv; 2018 Nov; 2(21):2904-2916. PubMed ID: 30396910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
    Leksa NC; Chiu PL; Bou-Assaf GM; Quan C; Liu Z; Goodman AB; Chambers MG; Tsutakawa SE; Hammel M; Peters RT; Walz T; Kulman JD
    J Thromb Haemost; 2017 Jun; 15(6):1167-1179. PubMed ID: 28397397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
    Hartholt RB; Wroblewska A; Herczenik E; Peyron I; Ten Brinke A; Rispens T; Nolte MA; Slot E; Claassens JW; Nimmerjahn F; Verbeek JS; Voorberg J
    J Thromb Haemost; 2017 Feb; 15(2):329-340. PubMed ID: 27868337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
    Chu SY; Vostiar I; Karki S; Moore GL; Lazar GA; Pong E; Joyce PF; Szymkowski DE; Desjarlais JR
    Mol Immunol; 2008 Sep; 45(15):3926-33. PubMed ID: 18691763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.
    Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A
    Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A.
    Ebbert PT; Xavier F; Malec LM; Seaman CD; Ragni MV
    Thromb Res; 2020 Nov; 195():51-54. PubMed ID: 32653601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
    Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
    Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.
    Meeks SL; Lacroix-Desmazes S
    Haemophilia; 2020 Nov; 26(6):958-965. PubMed ID: 32885562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.